What is Precision Neuroscience Corporation?
Precision Neuroscience Corporation is at the forefront of developing and commercializing minimally invasive brain-computer interfaces (BCI). The company's mission is to address critical unmet clinical needs by creating BCI solutions for conditions such as refractory epilepsy, blindness, paralysis, cognitive impairment, and impulse-control disorders. With a decade-long foundation in building its intellectual property portfolio, Precision Neuroscience is well-capitalized to advance its groundbreaking technology from development to market.
How much funding has Precision Neuroscience Corporation raised?
Precision Neuroscience Corporation has raised a total of $155M across 3 funding rounds:
Series A
$12M
Series B
$41M
Series C
$102M
Series A (2021): $12M with participation from Steadview Capital and B Capital Group
Series B (2023): $41M led by Forepont Capital Partners, Mubadala GE Capital PJSC, Draper Associates, and Alumni Ventures
Series C (2024): $102M supported by General Equity Holdings and B Capital Group
Key Investors in Precision Neuroscience Corporation
Steadview Capital
Steadview Capital is an investment firm focused on building generational companies in both public and private markets, with a presence in the US and India. They partner with visionary founders and are known for their integrated investing framework.
B Capital Group
B Capital is a venture capital firm that invests in early and late-stage companies across Technology, Healthcare, and Climate sectors, aiming to support entrepreneurs throughout the company-building lifecycle with over $8 billion in assets under management.
General Equity Holdings
General Equity Holdings LP operates within the Holding Companies industry, headquartered in Brooklyn, New York, and is involved in various business ventures.
What's next for Precision Neuroscience Corporation?
The substantial enterprise-level funding positions Precision Neuroscience Corporation for accelerated growth and market penetration. This strategic investment is expected to fuel further research and development, scale manufacturing capabilities, and expand clinical trials. The company's focus on addressing intractable medical conditions suggests a trajectory aimed at significant market disruption and improving patient outcomes globally. Future endeavors will likely involve navigating regulatory pathways and forging key partnerships to bring their innovative BCI solutions to a wider patient population.
See full Precision Neuroscience Corporation company page
